Companies › Prestige Biopharma
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bevacizumab (HD204) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Lung Cancer | – |
| PBP1510 Anti-PAUF monoclonal antibody | PAUF | Phase 1 | Pancreatic Cancer | Dec 2026 |
| Adalimumab (PBP1502) TNF-alpha inhibitor | TNF | Phase 1 | Healthy Volunteers | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03390686 | Bevacizumab (HD204) | Phase 3 | Lung Cancer | Oncology | Jul 2024 |
| NCT05141149 | PBP1510 | Phase 1 | Pancreatic Cancer | Oncology | Dec 2026 |
| NCT05108259 | Adalimumab (PBP1502) | Phase 1 | Healthy Volunteers | Other | Jun 2027 |
Cash of $47m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Nurix Therapeutics Exelixis Immunocore Genmab Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.